Weekly SARS-CoV-2 RNA detection assays from nasopharyngeal swabs were performed. participants in the IC with a probable newly acquired SARS-CoV-2 RNA-proven infection was 20% (95% IC 5.7C43.6%) at the end of the 7-week follow up period. The incidence reinfection rate was 28.6 (95% IC 7.8C73.2) cases per 1000 person-week. Despite detectable IgG antibodies against SARS-CoV-2 participants highly exposed to SARS-CoV-2 may develop a newly acquired SARS-CoV-2 RNA detection episode during the first months after the initial infection. = 20)= 20)0.11). Open in a separate window Figure 1 Timeline of participants with no evidence of newly acquired illness or early probable reinfection in the IC cohort. TMA: transcription-mediated amplification, PCR: polymerase chain reaction. Open in a separate window Number 2 Timeline of participants with late newly acquired illness. TMA: transcription-mediated amplification, PCR: polymerase chain reaction. 3.3. Serology Results At the time of inclusion, 18 out of 20 participants in the IC experienced an available initial serology, and 55.6% (10/18) had specific IgG antibodies against SARS-CoV-2. At the end of the 7-week study 11 out of 17 (64.7%) had positive IgG antibodies against SARS-CoV-2. Four participants experienced bad IgG antibodies against SARS-CoV-2 throughout the period of the study, 4 participants seroconverted, and 1 participant experienced undetectable IgG antibodies against SARS-CoV-2 at the end of the study period. All Methoxy-PEPy participants in the HC experienced bad IgG antibodies against SARS-CoV-2 at the beginning and at the end of the study, except for one participant who experienced a positive anti-SARS-CoV-2 IgG at the end of the study, although all 8 RT-PCR from nasopharyngeal swabs were bad during the study period. This participant experienced positive total antibodies against SARS-CoV-2 at the time of inclusion with bad IgG antibodies, emphasizing the possibility of a recent asymptomatic SARS-CoV-2 illness before participating in the study. 4. Discussion With this statement, we describe a prospective study involving 40 health care workers taking care of COVID19 individuals. Twenty participants had been previously diagnosed with symptomatic SARS-CoV-2 illness confirmed by molecular checks and 20 participants without evidence of previous SARS-CoV-2 illness were included as Methoxy-PEPy settings. In the HC group, all participants experienced RNA-detection assays and IgG antibodies against SARS-CoV-2 bad at the beginning of the study. Based on our definition of probable newly acquired SARS-CoV-2 illness, 4 participants could be classified probable newly acquired SARS-CoV-2 illness during the 7-week study period; therefore, the incidence rate of reinfection in the 7-week study was 28.6 instances 1000 person-week in our study population. When including the self-reporting period, 6 participants fulfilled the probable newly acquired SARS-CoV-2 illness. Persistence of detectable of SARS-CoV-2 RNA in nasopharyngeal samples has been reported for long periods, especially in individuals with impaired immune systems. However, follow up periods are usually short, covering only the 1st weeks of the illness [13,14]. In a recent statement by Kim et al., hospitalized participants with Methoxy-PEPy COVID19 were repeatedly sampled to assess viral dropping and viability in viral tradition. From symptoms onset, the median time to SARS-CoV-2 RT-PCR clearance occurred on day time 34 (lower limit of 95% CI becoming the 24th day time, upper limit was not computable) in 50% of the individuals [15]. In our study the 4 participants with probable newly SARS-CoV-2 infections during the 7-week study experienced at least 55 days between the onset of symptoms and the SARS-CoV-2 RNA detection assay that led to reinfection suspicion, and 3 out of these 4 probable instances of reinfection experienced several bad RNA tests in between, reinforcing the likelihood of reinfections rather than remnants from your FKBP4 1st illness. The cases 8, 17 and 27 are worthy of special attention since they experienced TMA-positive swab nasopharyngeal samples several months after the 1st episode. In individual 17, RT-PCR was also positive with Methoxy-PEPy Ct ideals consistent with an acute illness. Patient 8 recalled a detailed contact with a positive COVID19 case before having a new positive SARS-CoV-2 RNA detection assay. Interestingly, viral shedding of the newly acquired SARS-CoV-2 illness in patient 17 and 27 was very short compared with data from your 1st episodes, suggesting that an early reinfection may have low infectivity potential. Besides, participants with a probable reinfection did not have any symptoms, unlike what happened in the 1st episode when all of them have slight symptoms. Our data suggest that reinfection in highly exposed subjects having a slight 1st episode can appear within the 12 weeks after the 1st episode, assisting observation from additional coronaviruses. Reinfections with seasonal coronaviruses have been reported even with the presence of high antibody titres [16]. In the HC cohort we did not find any newly acquired SARS-CoV-2 illness,.